---
document_datetime: 2023-09-21 18:21:48
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_en.pdf
document_name: pandemrix-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.4081988
conversion_datetime: 2025-12-18 11:30:59.218049
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

## EMEA Number

## Package size

EU/1/08/452/001

--

1

suspension : 2.5 ml

emulsion : 2.5 ml

50 vials (suspension)

+

2 x 25 vials (emulsion)

--

1

3.75 µg HA

After mixing, 1 dose (0.5 ml) contains:

Split influenza virus, inactivated, containing antigen * equivalent to:

A/California/7/2009 (H1N1)v-like strain (X-179A)

*

propagated in eggs

**

haemagglutinin

AS03 adjuvant composed of squalene (10.69 milligrams), DLα -tocopherol (11.86 milligrams) and polysorbate 80 (4.86 milligrams)

Invented name Strength Pharmaceutical Form Route of Administration Packaging Content Pandemrix Suspension and emulsion for emulsion for injection Intramuscular use suspension (H1N1): vial (glass); emulsion (adjuvant): vial (glass) 3.75 micrograms ** Medicinal product no longer authorised